Pharma

Your Article Summary

See Latest Articles

New Study Shows ENBREL (etanercept) Is More Effective than a DMARD in the Treatment of Symptoms of Ankylosing Spondylitis Patients
Corporate News Releases - The Healthcare Sales & Marketing Network, 10/28/08

New safety and efficacy data for active ankylosing spondylitis (AS) patients treated with ENBREL (etanercept) were presented at the American College of Rheumatology (ACR) Scientific Meeting, 24-29 October, in San Francisco, CA. Data from a separate study presented at ACR showed that active AS patients treated with ENBREL experienced improvement in the signs and symptoms of their disease that were achieved and maintained for up to five years (252 to 264 weeks) of therapy.

Today in Marketing/Media/ROI...keeping you current

Receive free subspecialty "5-minute updates" via email

Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic
Shire, 12/03/09

Prodesses ProParaflu+(TM) Assay Cleared for US Marketing by FDA
Gen-Probe, 12/03/09

Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/25/09

 See all of Marketing/Media/ROI

Today in Physician/Patient Trends...keeping you current

Receive free subspecialty "5-minute updates" via email

Surgical and minimally invasive treatments for Peyronie's disease
Current Opinion in Urology, 11/19/09

Trends in prescribing and self-poisoning in relation to UK regulatory authority warnings against use of SSRI antidepressants in under-18-year-olds
British Journal of Clinical Pharmacology, 11/02/09

Derivation and Validation of the ASK-12 Adherence Barrier Survey
Annals of Pharmacotherapy, 10/15/09

 See all of Physician/Patient Trends